6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations
Bocchino M, Cobuccio R, De Martino M, Rea G, Matarese A, Canora A, Vitale C, Stanziola A, Sanduzzi A. Eur Res Journal, 2014 vol. 44 no. Suppl 58. BACKGROUND: Despite there is no definitive reference to the role of the 6-minute walk test (6MWT), it is frequently used to assess overall cardiopulmonary fitness and predict outcome in patients with diffuse interstitial lung diseases. AIM: Aim of the present study was to assess 6MWT performance with the Spiropalm device (that allows a combined evaluation of lung function parameters and pulse-oxymetry) in a group of patients affected by clinically stable idiopathic pulmonary fibrosis (n=15) and fibrotic non specific interstitial pneumonia (n=8). RESULTS: Overall, there were 17 males with a mean age±SD: 65±9yrs. Twelve were ex-smokers. Significant O2 desaturation was detectable in all cases (p<0.0001) with a mean distance walked of 404 m (78% of predicted) accounting for a 6MW work of 30685 kg*m. Ventilation and tidal volume were significantly increased at the end of 6MWT (15.3 vs 45.6 L/min and 0.6 vs 1.1 L, respectively), while the respiratory reserve was decreased (77 vs 35 %, p<0.0001). The distance-saturation product (DSP), that is the product of distance walked and lowest O2 saturation, was 322±110 m%, while the desaturation-distance ratio (DDR), that is the ratio between the desaturation area (difference between maximal SpO2 and patient's SpO2 every 2 seconds) and distance walked, was 8.5±5.5. DDR was inversely correlated with both FVC and DLCO (r=-0.5, p=0.04, and r=-0.66, p=0.004). A positive correlation was instead found with the composite physiologic index (r=0.66, p=0.006). CONCLUSIONS: Spiropalm may be successfully applied to ameliorate 6MWT performance in fibrotic idiopathic interstitial pneumonias. Performance upon incremental oxygen supplementation should be investigated.
Is measuring ventilation during the six minutes walking test (6MWT) important?
Stroescu C, Croitoru A, Ionita D. Eur Res Journal, 2014 Vol 38 Issue Suppl 55 . BACKGROUND: 6MWD and FEV1 are used as a one-time measure of functional status, as predictors of morbidity and mortality, and for measuring the response to medical interventions. The additional value of ventilation (VE) monitoring during the 6MWT is unknown. AIM: Evaluation of VE during the 6MWT and it's correlation with the validated parameters (6MWD and FEV1). METHOD: Patients (P) and healthy subjects (H) performed two standard 6MWT (S6MWT) and one 6MWT with VE monitoring (V6MWT), at minimum 1 hour intervals. The inspiratory capacity (IC) was measured before and after the V6MWT. VE profile and correlations between parameters were assessed. RESULTS: 23P (15 COPD cases) and 5H performed the tests. The baseline VE did not correlate with FEV1 and 6MWD nor with the baseline or end-of-test IC. Most subjects reached a VE plateau within the first 3 minutes of the test. The time to a stable VE did not correlate with the V6MWD or FEV1, but with baseline IC (r 0.428). The peak VE, as well as the difference between initial and final (delta) VE, did however significantly correlate with FEV1 (r 0.696 and 0.686 respectively) and 6MWD (r 0.515 and 0.476 respectively). Strong correlations were found between FEV1, V6MWD and baseline and end-of-test IC (r > 0,7), but not with the delta IC. The correlation of ventilatory parameters (IC, peak VE, delta VE) with the 6MWD was proven to be FEV1 dependent as, when controlled for FEV1, these correlations did not remain significant. CONCLUSIONS: Some ventilatory parameters measured during the 6MWT did correlate with the 6MWD and FEV1. The importance of VE profile evaluation during the 6MWT needs further assessment.
Is there a difference between the results of the standard six minutes walking test (S6MWT) and the test with ventilation monitoring (V6MWT)?
Stroescu C, Croitoru A, Ionita D. Eur Res Journal, 2014 Vol 38 Issue Suppl 55. BACKGROUND: 6MWT is a validated test for the evaluation and monitoring of patients with cardiovascular and respiratory conditions. The standard test evaluates the initial and final heart rate (HR) and oxygen saturation (SaO2), and does not measure ventilation. AIM: To assess (a) the similarities of the main parameters between S6MWT and V6MWT and (b) the mask-related discomfort during V6MWT. SUBJECTS AND METHOD: 23 patients (P) with respiratory diseases (15 COPD cases) and 5 healthy subjects (H) performed two S6MWT and one V6MWT, at 1 hour intervals. 6MWT distance (6MWD), initial and final HR, SaO2 and symptoms, and the mask-related discomfort were recorded. RESULTS: The mean 6MWD was 9 meters longer in S6MWT than in V6MWT (range -65, +135 m). In 7P (30%) the 6MWD was significantly different (>50 m) between the tests, with 5 P (22%) walking less and 2P walking more at the V6MWT. The mean initial and final symptom scores were similar between the tests (difference <0.5 points). At the end of V6MWT, 8P (35%) had higher dyspnoea scores and 5P had higher scores for both dyspnea and fatigue. The mean desaturation was similar between the tests, but 7P (30%) desaturated more at V6MWT (difference >4%). The mean initial and final HR was similar, but 7P had higher initial HR and 9P higher final HR at V6MWT. Mask-related discomfort was minor in 20P and 4H (86% tests), moderate in 2P and 1H, and major in 1P.
